首页 赛拉喜(usCYCC)-基本信息

赛拉喜(usCYCC)-基本信息

日报更新时间:

周报更新时间:01-23 11:54

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

中文名称:赛拉喜


英文名称:Cyclacel Pharmaceuticals


行业:医疗


简介:Cyclacel Pharmaceuticals, Inc.是一家处于发展阶段的生物制药公司,致力于用于治疗人类癌症和其它重大疾病的新药和与机体有关的药品的开发和商业化


电话:1-908-5177330


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Cyclacel Pharmaceuticals, Inc.总部位于新泽西州的Berkeley Heights,公司的业务发展和医疗及监管职能也在这里,公司的主要研究设施位于苏格兰的Dundee,这里也是Cyclacel制药公司的转译研究和临床前活动地点。Cyclacel制药公司是一家生物技术公司,开发癌症治疗药物和疗法,Cyclacel由Merlin Ventures and Cancer Research Campaign Technology、University of Dundee、University of Glasgow以及David Lane教授共同创立。主要股东包括Goldman Sachs Group、Tang Capital Management、Redmile Group 和 Ayer Capital Management。Cyclacel Pharmaceuticals公司正在开发“机制靶向药物”,以帮助打击癌症和其他严重疾病,如糖尿病和艾滋病毒。赛拉喜Cyclacel Pharmaceuticals候选产品: Cyclacel Pharmaceuticals主要候选产品为Sapacitabine (CYC682),用于老年急性髓性白血病(AML)治疗,目前已完成III期临床试验招募,在SPA下与FDA一起进行,作为老年急性骨髓性白血病(AML)的一线治疗产品;亦用于治疗其他适应症,包括骨髓增生异常综合征(MDS)。 Cyclacel的产品线还包括口服seliciclib方案,目前处于与sapacitabine联合在同源重组(Homologous Recombination,HR)治疗缺陷型乳腺癌、卵巢癌和胰腺癌(包括BRCA阳性肿瘤)患者的I期临床研究中。 CYC065,一种新型CDK2 / 9抑制剂,目前处于治疗血液恶性肿瘤和实体瘤的I期临床试验阶段。

交易日期 交易人 职位 类型 交易份额 价格
2017-07-18 EASTERN CAPITAL LTD Beneficial Owner of More than 10% Class Buy 850000 2.00

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Morgan Stanley - Brokerage Accounts 76 -- -32 -29.63% 2019-03-31
Northern Trust Corp 13399 0.08% -- -- 2019-03-31
Northern Trust Investments Inc 13741 0.08% 24 0.17% 2019-07-31
CWM, LLC duplicate 15000 0.09% 15000 -- 2019-03-31
Geode Capital Management, LLC 21692 0.13% -21692 -50.00% 2019-03-31
Virtu Financial LLC 23178 0.13% -13491 -36.79% 2019-03-31
Fidelity Management & Research Company 80758 0.47% -- -- 2019-07-31
Vanguard Group Inc 114157 0.66% 193 0.17% 2019-03-31
Renaissance Technologies Corp 604200 3.51% 393500 186.76% 2019-03-31
Northern Trust Investments N A 13399 0.08% -- -- 2019-03-31
TWO SIGMA SECURITIES, LLC 12717 0.07% 12717 -- 2019-03-31
Citadel Advisors Llc 11621 0.07% -6503 -35.88% 2019-03-31
State Street Global Advisors 206 -- -- -- 2019-07-31
Tci Wealth Advisors Inc 600 -- 600 -- 2019-03-31
BlackRock Fund Advisors 796 -- -- -- 2019-07-31
BlackRock Inc 796 -- 796 -- 2019-03-31
UBS Group AG 1074 0.01% -7019 -86.73% 2019-03-31
BlackRock Asset Management Canada Ltd 3184 0.02% -- -- 2019-07-31
Fidelity Management and Research Company 5159 0.03% 5159 -- 2019-03-31
FMR Inc 5159 0.03% 5159 -- 2019-03-31
Raymond James Finl Svs Advisors, Inc. 50125 0.29% -- -- 2018-12-31
Vanguard Investments Australia Ltd 7052 0.04% 6944 6429.63% 2019-06-30
Panagora Asset Management Inc 27173 0.16% 9733 55.81% 2018-12-31
Macquarie Funds Management HK Ltd. 2900 0.02% 2900 -- 2018-12-31
Bank of America Corporation 179 -- -153 -46.08% 2018-12-31
Macquarie Group Ltd 2900 0.02% 2900 -- 2018-12-31
Deutsche Bank AG 113 -- 110 3666.67% 2018-12-31
Bt Alex Brown Inc 113 -- 113 -- 2018-12-31
D'Orazio & Associates Inc 100 -- -- -- 2018-09-30
Dimensional Fund Advisors LP 2509 0.02% -2700 -51.83% 2019-02-28
Susquehanna Financial Group, LLLP 32369 0.26% 20186 165.69% 2018-09-30
Susquehanna International Group, LLP 32369 0.26% 20186 165.69% 2018-09-30
Invesco Capital Management LLC 2257 0.02% -- -- 2019-01-31
Dimensional Fund Advisors, Inc. 12240 0.10% -- -- 2018-09-30
Vanguard 1858 0.01% -- -- 2018-11-30
UBS Securities LLC 10380 0.08% 7424 251.15% 2018-06-30
Sabby Management LLC 25000 0.20% 25000 -- 2018-06-30
Wedbush Morgan Securities Inc 21000 0.17% 21000 -- 2018-03-31
Eastern Capital LTD 2167261 19.01% 850000 64.53% 2017-08-10
Tang Capital Partners LP 336747 2.83% -223153 -39.86% 2017-11-16
Guggenheim Funds Investment Advisors LLC 2579 0.02% -- -- 2018-09-14
Signet Financial Management, LLC 23 -- -- -- 2018-06-30
Morgan Stanley Smith Barney LLC 229 -- -- -- 2018-06-30
Managed Account Advisors LLC 83 -- 83 -- 2018-06-30
Royal Bank Of Canada 1 -- -- -- 2018-03-31
Morgan Stanley & Co Inc 31 -- 31 -- 2017-12-31
Oxford Asset Management, LLC 31827 0.26% 31827 -- 2017-12-31
Two Sigma Investments LLC 70310 0.58% 70310 -- 2017-12-31
TANG CAPITAL MANAGEMENT LLC 559900 4.79% -- -- 2017-09-30
WFG Advisors, LP 416 0.01% -- -- 2017-06-30
Alambic Investment Management, L.P. 12700 0.30% 12700 -- 2016-09-30
KCG AMERICAS LLC 19032 0.45% 19032 -- 2016-09-30
IsZo Capital Management LP 169547 3.99% 169547 -- 2016-09-30
Tower Research Capital LLC 300 0.01% 300 -- 2016-09-30
Kenneth B. Dart 5607143 4.00% 4822143 0.20% 1999-11-30
Heights Capital Management, Inc. 3026260 4.00% 2602584 0.10% 1999-11-30
Hal Mintz 3200000 4.00% 2752000 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Vanguard Total Stock Market Index Fund -- -- -7052 -100.00% 2019-06-30
NT Ext Equity Market Index Fund - L 10045 0.06% -- -- 2019-06-30
Vanguard Extended Market Index Fund 106172 0.62% -- -- 2019-06-30
NT US Market Cap Index Fund - Lending 2899 0.02% -- -- 2019-06-30
iShares Core S&P Total US Stock Mkt ETF 796 -- -- -- 2019-07-30
iShares Core MSCI AllCntry Wld exCan ETF 796 -- -- -- 2019-05-30
iShares Core Growth ETF Portfolio 796 -- -- -- 2019-05-30
iShares Core Balanced ETF Portfolio 796 -- -- -- 2019-05-30
iShares Core S&P US Total Market ETF 796 -- -- -- 2019-05-30
Fidelity 704 -- -- -- 2019-06-30
NT Extended Equity Market Idx Fund - NL 455 -- -- -- 2019-06-30
DFA US Vector Equity Fund -- -- -2700 -100.00% 2018-12-31
Vanguard Balanced Index Fund -- -- -7684 -100.00% 2019-06-30
Vanguard Instl Total Stock Market Idx Fd -- -- -193 -100.00% 2019-06-30
Invesco Wilshire Micro-Cap ETF -- -- -2257 -100.00% 2019-02-22
NT US Market Cap Index Fund - NL 16 -- -- -- 2018-12-31
State Street U.S. Extended Market Index 206 -- -- -- 2019-07-31
NT Ext Equity Mkt Fd - DC - NL 326 -- 24 7.95% 2019-06-30
NT Ext Equity Mkt Idx Fd - DC - NL 326 -- 24 7.95% 2019-06-30
The Vanguard Total Stock Market Index -- -- -1858 -100.00% 2018-06-30
DFA Tax Managed US Small Cap Portfolio 1633 0.01% -- -- 2017-07-31
DFA T.A. US Core Equity 2 Portfolio 2509 0.02% -- -- 2017-11-30
DFA US Small Cap Portfolio 6748 0.06% -- -- 2017-07-31
DFA US Micro Cap Portfolio 7783 0.06% -- -- 2017-07-31
Vanguard Total Stock Mkt Idx 262933 2.19% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 106172 0.88% -- -- 2018-07-31
Vanguard Balanced Index Inv 3392 0.03% -- -- 2018-07-31
DFA US Vector Equity I 2700 0.02% -- -- 2018-07-31
Fidelity Spartan 960 0.01% -- -- 2018-07-31
Wilshire Micro-Cap ETF 2579 0.02% -- -- 2018-09-14
iShares Core S&P Total US Stock Mkt 796 0.01% -- -- 2018-09-12
SSgA U.S. Total Market Index Fd Class I 57 -- -4 -6.56% 2017-12-31
DFA T.A. US Core Equity 2 I 2509 0.02% -- -- 2017-11-30
DFA US Micro Cap I 7783 0.18% -- -- 2016-12-31
DFA US Small Cap I 6748 0.16% -- -- 2016-12-31
DFA US Targeted Value I 4240 0.10% -- -- 2016-12-31
DFA Tax-Managed US Small Cap 1633 0.04% -- -- 2016-12-31
Fidelity® Nasdaq Composite Tr Stk Fund 684 -- -- -- 2015-09-30
Vanguard US Equity Index 1700 -- -- -- 2015-07-31
VAM Americas All Cap 3000 -- -- -- 2015-09-30
Fidelity® NASDAQ Composite Index® Fund 5706 -- -- -- 2015-09-30
Fidelity Spartan® Total Market Idx Fund 11529 -- -- -- 2015-09-30
The Vanguard - Total Stk Mkt Idx Trust. CF 22300 0.10% -- -- 2015-09-30
Fidelity Spartan® Extended Mkt Indx Fd 68516 0.20% -- -- 2015-09-30

Judy Chiao Presently, Judy Chiao holds the position of VP-Clinical Development & Regulatory Affairs at Cyclacel Pharmaceuticals, Inc. In her past career she held the position of VP-Oncology Clinical Research & Development at Aton Pharma, Inc. She received an undergraduate degree from Columbia University and a doctorate from Harvard Medical School.
Gregory T. Hradsky Gregory T. Hradsky founded Bellport Capital Advisors LLC. Mr. Hradsky is on the board of Costar Technologies, Inc. and Cyclacel Pharmaceuticals, Inc. In his past career Mr. Hradsky held the position of Managing Partner at Bellport Capital Advisors LLC, Managing Director at UBS Securities LLC, Vice President at Avenue Capital Management II LP, Vice President at Avenue Capital Management LLC (Private Equity) and Member-Distressed Securities Group at First Boston Corp. He received an undergraduate degree from Loyola University Maryland, Inc. and an MBA from The Wharton School of the University of Pennsylvania.
Christopher S. Henney Christopher S. Henney is an entrepreneur and businessperson who founded Immunex Corp., ICOS Corp. and Dendreon Corp. and who has been the head of 6 different companies. Dr. Henney is on the board of Anthera Pharmaceuticals, Inc., Cyclacel Pharmaceuticals, Inc. and Prothena Corp. Plc. In the past Christopher S. Henney occupied the position of Chairman for Allostera Pharma, Inc., Chairman at SGX Pharmaceuticals, Inc., Chairman of Biomira, Inc., Chairman & Chief Executive Officer at Dendreon Corp., Chairman, President & Chief Executive Officer for Cascadian Therapeutics, Inc., Chairman for Xcyte Therapies, Inc., Director, Executive VP & Scientific Director at ICOS Corp., Vice Chairman & Scientific Director at Immunex Corp., Professor at Fred Hutchinson Cancer Research Center, Professor at The Johns Hopkins University and Professor at the University of Washington. Dr. Henney received a doctorate and an undergraduate degree from the University of Birmingham.
David C. U'Prichard Dr. David C. U'Prichard is Independent cat Audeo Oncology, Inc., a Director at Anesiva, Inc., Founding Partner at Druid BioVentures LLC, Chairman at Cyclacel Pharmaceuticals, Inc., Venture Partner & Senior Advisor at Red Abbey Venture Partners LLC, Chairman at Orca Pharmaceuticals Ltd. and President at Druid Consulting LLC. He is on the Board of Directors at Audeo Oncology, Inc., iCeutica, Inc., Anesiva, Inc., Angstrom Pharmaceuticals, Inc., BioMotiv LLC, Iroko Pharmaceuticals LLC, Iroko Pharmaceuticals, Inc., Ocimum Bio Solutions (India) Ltd., Ocimum Biosolutions, Inc., International House of Philadelphia and The Wilma Theater, Inc. Dr. U'Prichard was previously employed as Independent Director by Life Technologies Corp., Chairman by Cyclacel Group Plc, Chairman by Oxagen Ltd., Chairman by Pennsylvania Biotechnology Association, Venture Partner by Apax Partners (UK) Ltd., Chief Executive Officer & Director by 3-Dimensional Pharmaceuticals, Inc., Chairman-Research & Development by Smithkline Beecham Pharmaceuticals (India) Ltd., Executive Vice President-Biomedical Research by ICI Pharmaceuticals, Director, EVP & Director-International Research by Zeneca Group Plc, Scientific Director & Senior Vice President by Nova Pharmaceutical Corp., an Associate Professor by Feinberg School of Medicine, Venture Partner by Care Capital LLC, Venture Partner by Apax Partners, Inc., and Non-Executive Director by Silence Therapeutics Plc. He also served on the board at Alpharma, Inc., Invitrogen Corp., Biotechnology Industry Organization, Atugen AG, CoGenesys, Inc., Guilford Pharmaceuticals, Inc., Life Sciences Research, Inc., Lynx Therapeutics, Inc., Naurex, Inc., Ocimum Bio Solutions (India) Ltd., Predict, Inc. and SMART Biosciences, Inc. He received his undergraduate degree from the University of Glasgow and a doctorate degree from the University of Kansas.
John Michael Middlecott Banham John Michael Middlecott Banham is a businessperson who has been at the head of 11 different companies is on the board of Cyclacel Pharmaceuticals, Inc., Merchant Trust Plc and Engenie Ltd. In his past career he was Chairman of Johnson Matthey Plc, Chairman at Kingfisher plc, Chairman for Whitbread Plc, Chairman of ECI Partners LLP and Chairman at ECI Ventures Ltd. (a subsidiary of ECI Partners LLP), Chairman for Sultan Scientific Ltd., Chairman at Spacelabs Healthcare, Inc., Chairman of Geest Ltd., Chairman for Tarmac Trading Ltd., Chairman of Westcountry Television Ltd., Chairman of Innoveas International Ltd. and Director General at Confederation of British Industry. He received an undergraduate degree from the University of Cambridge.
Christopher S. Henney Christopher S. Henney is an entrepreneur and businessperson who founded Immunex Corp., ICOS Corp. and Dendreon Corp. and who has been the head of 6 different companies. Dr. Henney is on the board of Anthera Pharmaceuticals, Inc., Cyclacel Pharmaceuticals, Inc. and Prothena Corp. Plc. In the past Christopher S. Henney occupied the position of Chairman for Allostera Pharma, Inc., Chairman at SGX Pharmaceuticals, Inc., Chairman of Biomira, Inc., Chairman & Chief Executive Officer at Dendreon Corp., Chairman, President & Chief Executive Officer for Cascadian Therapeutics, Inc., Chairman for Xcyte Therapies, Inc., Director, Executive VP & Scientific Director at ICOS Corp., Vice Chairman & Scientific Director at Immunex Corp., Professor at Fred Hutchinson Cancer Research Center, Professor at The Johns Hopkins University and Professor at the University of Washington. Dr. Henney received a doctorate and an undergraduate degree from the University of Birmingham.
Lloyd M. Sems Lloyd M. Sems founded Capital Edge LLC and Sems Capital LLC. Currently, he is President of Capital Edge LLC and President & Chief Investment Officer at Sems Capital LLC. He is also on the board of Cyclacel Pharmaceuticals, Inc. and Managing Member & General Partner at Sems Diversified Value LP. He previously occupied the position of Director of Research & Portfolio Manager at Watchpoint Asset Management LLC. He received an undergraduate degree from Albright College.
Spiro Rombotis Presently, Spiro Rombotis holds the position of President, Chief Executive Officer & Director at Cyclacel Pharmaceuticals, Inc. He is also on the board of BioNJ, Inc. In his past career he occupied the position of Head-Business Development for Novartis AG, VP-Pharmaceuticals-Central & Eastern Europe at Bristol-Myers Squibb Co., President & Chief Executive Officer for Cyclacel Group Plc, MD-Europe & Director-Japanese Joint Venture at The Liposome Co., Inc. and Head-Corporate Development at Centocor, Inc. Mr. Rombotis received an undergraduate degree from Williams College and a graduate degree and an MBA from Kellogg School of Management.
Paul McBarron Paul McBarron is Chief Operating, Financial Officer & Secretary at Cyclacel Pharmaceuticals, Inc. Mr. McBarron previously was Chief Operating Officer, Secretary & Executive VP at Cyclacel Group Plc and Finance Director & Controller at Shire Plc.
Christopher S. Henney Christopher S. Henney is an entrepreneur and businessperson who founded Immunex Corp., ICOS Corp. and Dendreon Corp. and who has been the head of 6 different companies. Dr. Henney is on the board of Anthera Pharmaceuticals, Inc., Cyclacel Pharmaceuticals, Inc. and Prothena Corp. Plc. In the past Christopher S. Henney occupied the position of Chairman for Allostera Pharma, Inc., Chairman at SGX Pharmaceuticals, Inc., Chairman of Biomira, Inc., Chairman & Chief Executive Officer at Dendreon Corp., Chairman, President & Chief Executive Officer for Cascadian Therapeutics, Inc., Chairman for Xcyte Therapies, Inc., Director, Executive VP & Scientific Director at ICOS Corp., Vice Chairman & Scientific Director at Immunex Corp., Professor at Fred Hutchinson Cancer Research Center, Professor at The Johns Hopkins University and Professor at the University of Washington. Dr. Henney received a doctorate and an undergraduate degree from the University of Birmingham.
Robert Jay Spiegel Robert Jay Spiegel founded Spiegel Consultants, LLC. Presently, he is Chairman at Vidac Pharma Ltd. and President at Spiegel Consultants, LLC. Dr. Spiegel is also on the board of Geron Corp., Avior Computing Corp., Sucampo Pharmaceuticals, Inc. and Cyclacel Pharmaceuticals, Inc. and Associate Professor at Weill Cornell Medical College. In the past he was Chairman for NexImmune, Inc., Chief Medical Officer for PTC Therapeutics, Inc., Chief Medical Officer & Senior Vice President of Schering-Plough Research Institute and Senior Vice President of Worldwide Clinical Research, Inc. Dr. Spiegel received an undergraduate degree from Yale University and a doctorate from the University of Pennsylvania.
Samuel L. Barker Dr. Samuel L. Barker is Independent Director at Cadence Pharmaceuticals, Inc., Independent Director at Lexicon Pharmaceuticals, Inc., and Strategic Advisor at Symphony Capital LLC. He is on the Board of Directors at Cadence Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., and The Cancer Institute of New Jersey. Dr. Barker was previously employed as a Principal by Clearview Projects, Inc., President by United States Pharmaceutical Group LLC, and EVP-Worldwide Franchise Management & Strategy by Bristol-Myers Squibb Co. He also served on the board at AtheroGenics, Inc. He received his undergraduate degree from Henderson State University (Arkansas), a graduate degree from The University of Arkansas, and a doctorate degree from Purdue University.
Samuel L. Barker Dr. Samuel L. Barker is Independent Director at Cadence Pharmaceuticals, Inc., Independent Director at Lexicon Pharmaceuticals, Inc., and Strategic Advisor at Symphony Capital LLC. He is on the Board of Directors at Cadence Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., and The Cancer Institute of New Jersey. Dr. Barker was previously employed as a Principal by Clearview Projects, Inc., President by United States Pharmaceutical Group LLC, and EVP-Worldwide Franchise Management & Strategy by Bristol-Myers Squibb Co. He also served on the board at AtheroGenics, Inc. He received his undergraduate degree from Henderson State University (Arkansas), a graduate degree from The University of Arkansas, and a doctorate degree from Purdue University.
Amartya Basu Amartya Basu is Senior Director-Business Development at Cyclacel Pharmaceuticals, Inc. Dr. Basu received an MBA from Rutgers University Graduate School of Banking and a doctorate from the University of Medicine & Dentistry of New Jersey.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐